{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-201840","form_type":"8-K","ticker":"ALKS","cik":"0001520262","company_name":"Alkermes plc.","filed_at":"2025-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.207787+00:00","generated_at":"2026-05-17T06:44:21.216514+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Alkermes appoints Joshua Reed as CFO effective September 15, 2025","bullets":["Reed will report to CEO Richard Pops and join the management committee.","He brings 30+ years finance experience; most recently CFO of Omega Therapeutics and Aldeyra Therapeutics, and earlier at Bristol Myers Squibb.","Base salary $615,000, target annual cash bonus 50% of base, new-hire equity grant valued at $3.5 million.","Blair C. Jackson, EVP/COO, had been serving as interim principal financial officer; Samuel Parisi remains interim principal accounting officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-201840","json":"https://secwatch.observer/filing/0001193125-25-201840.json","markdown":"https://secwatch.observer/filing/0001193125-25-201840.md","text":"https://secwatch.observer/filing/0001193125-25-201840.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1520262/000119312525201840/0001193125-25-201840-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1520262/000119312525201840/alks-20250912.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:44:21.216514+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}